Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Actimmune Clear all
Terminated Phase 4 Interventional Results available

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042
View directory record Official record
Conditions
IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions
IFN-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 23, 2026, 5:53 AM EDT
Not listed Phase 2 Interventional

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

NCT00753467
View directory record Official record
Conditions
Hepatitis B
Interventions
IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2010 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

NCT00003414
View directory record Official record
Conditions
Graft Versus Host Disease, Lymphoma
Interventions
aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

NCT00111397
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Cytokine therapy, Interferon Gamma, GM-CSF
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 5:53 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers

NCT01929382
View directory record Official record
Conditions
Adverse Effects in the Therapeutic Use of Interferon
Interventions
interferon gamma 1b
Drug
Lead sponsor
Vidara Therapeutics Research Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT02143518
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-GST-1/Alhydrogel®, CpG 10104
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 23, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

NCT00047632
View directory record Official record
Conditions
Ovarian Carcinoma, Peritoneal Carcinoma
Interventions
Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
Female only
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of IFN-γ on Innate Immune Cells

NCT02609932
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Administration of drug (Interferon-gamma 1-b) subcutaneously
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Treatment of Crohn's Disease

NCT00007163
View directory record Official record
Conditions
Crohn's Disease
Interventions
J695
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

NCT01376362
View directory record Official record
Conditions
Anterior Uveitis, Uveitis
Interventions
Interferon Gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

NCT00084279
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
Drug
Lead sponsor
InterMune
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Sep 23, 2026, 5:53 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Cell Responses to IFN-gamma

NCT01317017
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Actimmune
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 23, 2026, 5:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

NCT04722029
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Adenovirus Specific T lymphocytes
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 23, 2026, 5:53 AM EDT
Terminated Early Phase 1 Interventional Results available

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

NCT01957709
View directory record Official record
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions
Laboratory Biomarker Analysis, Recombinant Interferon Gamma
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 2Phase 3 Interventional

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

NCT00070187
View directory record Official record
Conditions
Lymphoma
Interventions
aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Not applicable Interventional

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

NCT00002433
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon gamma-1b
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:53 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Anti-viral T-cell Therapy by Gamma Capture

NCT06027879
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Specific T- Lymphocytes
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 23, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

NCT00076635
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
Interventions
Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

NCT03063632
View directory record Official record
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

NCT03312751
View directory record Official record
Conditions
Primary Hemophagocytic Lymphohistiocytosis
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 18 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 23, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

Emapalumab Prevention of CAR-T Cell Associated Toxicities

NCT06550141
View directory record Official record
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Interventions
Emapalumab, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

NCT01965327
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Interferon Gamma-1b
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 23, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

NCT00001905
View directory record Official record
Conditions
Leukocyte Adhesion Deficiency Syndrome
Interventions
Interferon gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 5:53 AM EDT